About Us


PCORI Emerging Health Care Innovation Brief -- With a background showing a human genome helix

The latest Emerging Health Care Innovation Brief highlights two potential treatments for early Alzheimer’s Disease (AD), the most common cause of dementia. It also causes declining cognitive function and the inability to perform activities of daily living.

The first experimental treatment, donanemab, is a humanized monoclonal antibody designed to bind amyloid-beta (Aβ) plaques and promote their clearance. It is intended to slow cognitive decline in patients with early AD.

The second experimental treatment, valiltramiprosate (ALZ-801), is an oral prodrug metabolized into tramiprosate, a compound that reportedly inhibits Aβ aggregation, thought to contribute to AD pathology.

View the Innovation Brief

This PCORI Emerging Health Care Innovation Brief is part of a series highlighting important topics of interest identified during the ongoing scanning and topic identification process or through a stakeholder survey process.

Useful Links

What's Happening at PCORI?

The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.

Subscribe to PCORI Emails


Hand pointing to email icon